QURE vs. OVID, CDT, ALDX, ACRV, IMMP, FHTX, ACIU, GTHX, TSVT, and GBIO
Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Ovid Therapeutics (OVID), Conduit Pharmaceuticals (CDT), Aldeyra Therapeutics (ALDX), Acrivon Therapeutics (ACRV), Immutep (IMMP), Foghorn Therapeutics (FHTX), AC Immune (ACIU), G1 Therapeutics (GTHX), 2seventy bio (TSVT), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Ovid Therapeutics (NASDAQ:OVID) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Ovid Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
uniQure received 293 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. Likewise, 70.75% of users gave uniQure an outperform vote while only 70.58% of users gave Ovid Therapeutics an outperform vote.
uniQure has a net margin of -1,947.09% compared to uniQure's net margin of -13,351.53%. uniQure's return on equity of -49.76% beat Ovid Therapeutics' return on equity.
Ovid Therapeutics has higher earnings, but lower revenue than uniQure. Ovid Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ovid Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Ovid Therapeutics and 0 mentions for uniQure. uniQure's average media sentiment score of 0.68 beat Ovid Therapeutics' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the media.
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 12.6% of Ovid Therapeutics shares are held by insiders. Comparatively, 4.1% of uniQure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ovid Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 182.13%. uniQure has a consensus target price of $32.00, suggesting a potential upside of 611.11%. Given Ovid Therapeutics' higher possible upside, analysts clearly believe uniQure is more favorable than Ovid Therapeutics.
Summary
uniQure beats Ovid Therapeutics on 10 of the 18 factors compared between the two stocks.
Get uniQure News Delivered to You Automatically
Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
